Advertisement

Ophthalmology Times Europe October 2022

October 2022

Positive interim data in Phase 2 BEHOLD trial investigating UBX1325 in DMO patients

September 10, 2022

12-week interim results of BEHOLD, a proof-of-concept Phase 2a study investigating the candidate UBX1325, provides a positive outlook for a novel senolytic approach for previously-treated patients with diabetic macular oedema.

Advertisement
Advertisement